<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432793</url>
  </required_header>
  <id_info>
    <org_study_id>0172</org_study_id>
    <nct_id>NCT03432793</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction (DDI) Study for TD-9855</brief_title>
  <official_title>A Phase 1, Fixed-Sequence, Open-Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD-9855 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the&#xD;
      PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess&#xD;
      the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and&#xD;
      non-smokers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">April 21, 2018</completion_date>
  <primary_completion_date type="Actual">April 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine</measure>
    <time_frame>Day 9 and Day 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between caffeine PK disposition and TD-9855 plasma exposure</measure>
    <time_frame>Day 9 and Day 24</time_frame>
    <description>Correlation co-efficient will be calculated between caffeine/paraxanthine ratio at 4hr after caffeine dose and TD-9855 plasma AUC on Day 9 and Day 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Drug Drug Interaction (DDI)</condition>
  <arm_group>
    <arm_group_label>TD-9855 + Fluvoxamine + Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male smokers will receive TD-9855, fluvoxamine, and caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-9855 + Itraconazole + Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male non-smokers will receive TD-9855, itraconazole, and caffeine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-9855</intervention_name>
    <description>oral tablet, QD</description>
    <arm_group_label>TD-9855 + Fluvoxamine + Caffeine</arm_group_label>
    <arm_group_label>TD-9855 + Itraconazole + Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>oral tablet, QD</description>
    <arm_group_label>TD-9855 + Fluvoxamine + Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>oral tablet solution, QD</description>
    <arm_group_label>TD-9855 + Itraconazole + Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>oral solution, single dose</description>
    <arm_group_label>TD-9855 + Fluvoxamine + Caffeine</arm_group_label>
    <arm_group_label>TD-9855 + Itraconazole + Caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to give written, signed informed consent&#xD;
&#xD;
          -  Male subjects 19 to 55 years of age (inclusive)&#xD;
&#xD;
          -  Body mass index 19 to 32 kg/m2 (inclusive), and weigh at least 55 kg&#xD;
&#xD;
          -  No clinically important abnormal physical findings as determined by the Principal&#xD;
             Investigator (PI) at the screening and Day -1 examinations&#xD;
&#xD;
          -  Negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human&#xD;
             immunodeficiency virus (HIV) antibody at screening.&#xD;
&#xD;
          -  No clinically important laboratory abnormalities as determined by the PI&#xD;
&#xD;
          -  Ability to communicate effectively with the Investigator and to comply with all study&#xD;
             requirements, restrictions, and direction of the clinic staff&#xD;
&#xD;
          -  Male subjects must abstain from sexual intercourse or use a highly effective method of&#xD;
             birth control&#xD;
&#xD;
          -  Male smokers: Subjects who self-report to have smoked &gt; 9 cigarettes per day for at&#xD;
             least 6 month prior to screening as confirmed by urine cotinine test at screening and&#xD;
             Day -1.&#xD;
&#xD;
          -  Male smokers: Subjects must be willing to continue consistent use of their tobacco&#xD;
             products throughout the study.&#xD;
&#xD;
          -  Additional inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human&#xD;
             immunodeficiency virus (HIV) antibody at screening.&#xD;
&#xD;
          -  History or presence of clinically significant respiratory, gastrointestinal, renal,&#xD;
             hepatic, hematologic, neurologic (including history of seizure and insomnia),&#xD;
             cardiovascular (including postural orthostatic hypotension or tachycardia),&#xD;
             psychiatric (including depression and known addictive disorders), musculoskeletal,&#xD;
             genitourinary (including urinary retention), immunologic, or dermatologic disorder.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the PI, would confound or interfere with&#xD;
             study participation; evaluation of safety, tolerability, or PK of the investigational&#xD;
             drug; or prevent compliance with the study protocol&#xD;
&#xD;
          -  Any history of suicide attempts/ideation or current suicidal ideation.&#xD;
&#xD;
          -  Have participated in another clinical trial of an investigational drug (or medical&#xD;
             device) within 30 days (or 5 half-lives of the investigational drug if longer than 30&#xD;
             days) prior to Screening, or are currently participating in another trial of an&#xD;
             investigational drug (or medical device), or intending to participate in another trial&#xD;
             of an investigational drug (or medical device) before completion of all scheduled&#xD;
             safety evaluations in this trial&#xD;
&#xD;
          -  Additional inclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DDI</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Fluvoxamine</keyword>
  <keyword>TD-9855</keyword>
  <keyword>Smoking</keyword>
  <keyword>Caffeine</keyword>
  <keyword>CYP1A2</keyword>
  <keyword>CYP3A4</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

